NUVL
Price
$90.42
Change
+$0.78 (+0.87%)
Updated
Oct 16, 04:59 PM (EDT)
Capitalization
6.52B
21 days until earnings call
Intraday Buy/Sell Signals
XENE
Price
$42.17
Change
+$0.27 (+0.64%)
Updated
Oct 16 closing price
Capitalization
3.25B
19 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

NUVL vs XENE

Header iconNUVL vs XENE Comparison
Open Charts NUVL vs XENEBanner chart's image
Nuvalent
Price$90.42
Change+$0.78 (+0.87%)
Volume$9.38K
Capitalization6.52B
Xenon Pharmaceuticals
Price$42.17
Change+$0.27 (+0.64%)
Volume$805.29K
Capitalization3.25B
NUVL vs XENE Comparison Chart in %
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NUVL vs. XENE commentary
Oct 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Hold and XENE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 17, 2025
Stock price -- (NUVL: $90.42 vs. XENE: $42.17)
Brand notoriety: NUVL and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 137% vs. XENE: 104%
Market capitalization -- NUVL: $6.52B vs. XENE: $3.25B
NUVL [@Biotechnology] is valued at $6.52B. XENE’s [@Biotechnology] market capitalization is $3.25B. The market cap for tickers in the [@Biotechnology] industry ranges from $104.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 2 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 2 green, 3 red.
According to our system of comparison, XENE is a better buy in the long-term than NUVL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 6 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • NUVL’s TA Score: 6 bullish, 4 bearish.
  • XENE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than XENE.

Price Growth

NUVL (@Biotechnology) experienced а +2.75% price change this week, while XENE (@Biotechnology) price change was +2.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.20%. For the same industry, the average monthly price growth was +16.20%, and the average quarterly price growth was +80.31%.

Reported Earning Dates

NUVL is expected to report earnings on Nov 06, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (-1.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($6.52B) has a higher market cap than XENE($3.25B). NUVL YTD gains are higher at: 15.508 vs. XENE (7.577). XENE has higher annual earnings (EBITDA): -315.5M vs. NUVL (-362.01M). NUVL has more cash in the bank: 1.01B vs. XENE (488M). XENE has higher revenues than NUVL: XENE (7.5M) vs NUVL (0).
NUVLXENENUVL / XENE
Capitalization6.52B3.25B200%
EBITDA-362.01M-315.5M115%
Gain YTD15.5087.577205%
P/E RatioN/AN/A-
Revenue07.5M-
Total Cash1.01B488M206%
Total DebtN/A8.72M-
FUNDAMENTALS RATINGS
XENE: Fundamental Ratings
XENE
OUTLOOK RATING
1..100
19
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
PROFIT vs RISK RATING
1..100
32
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
43
P/E GROWTH RATING
1..100
6
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NUVLXENE
RSI
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 1 day ago
70%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 1 day ago
69%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 1 day ago
72%
Declines
ODDS (%)
Bearish Trend 10 days ago
78%
Bearish Trend 10 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TEMIX30.32N/A
N/A
Franklin Mutual International Value A
FGREX9.20N/A
N/A
Invesco Global Real Estate R6
BLNAX13.80N/A
N/A
Meeder Balanced Adviser
HAOYX23.90N/A
N/A
Hartford International Opportunities Y
JLGQX91.95N/A
N/A
JPMorgan Large Cap Growth R4

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XENE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+0.87%
XENE - NUVL
61%
Loosely correlated
+0.64%
CGON - NUVL
60%
Loosely correlated
-2.79%
RVMD - NUVL
59%
Loosely correlated
+0.24%
XNCR - NUVL
58%
Loosely correlated
+6.03%
IDYA - NUVL
57%
Loosely correlated
-2.43%
More